A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

NCT06392477 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
96
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi